Pep2Tango Therapeutics, a Potomac, MD-based startup focused on weight loss therapies, received an investment from Versant Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to develop its novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions.
Led by President, CEO and Chairperson Cristina Rondinone, Ph.D., and CSO Soumitra Ghosh, Ph.D., Pep2Tango Therapeutics is a biotechnology company aiming to develop new peptide drugs that target unmet medical needs, including for metabolic, endocrine, CNS and cardiovascular disorders. Its novel drug development approach for obesity focuses on unimolecular peptides that target multiple receptors, allowing for weight loss efficacy, muscle mass preservation, improved tolerability, and streamlined development and manufacturability.
The company is focused on CMC development activities to scale up drug candidate manufacturing and on running IND-enabling studies for a rapid transition to first-in-human clinical studies. An IND submission is expected in 2025.
Dr. Rondinone previously was president of Cellarity, and SVP and head of cardiovascular, renal and metabolic diseases at AstraZeneca plc. Prior to that, she held roles of increasing responsibility in cardio-metabolic disease research and development at MedImmune Inc., Roche and Abbott Laboratories, where she led the research and development of multiple molecules that moved to clinical trials including Rezdiffra™, dorzagliatin and bentracimab.
Dr. Ghosh is a co-founder of multiple biotech companies and served as executive director for research at Amylin Pharmaceuticals Inc., where he was involved in development efforts culminating in the approvals of Byetta®, Symlin®, Bydureon® and Myalept®. Dr. Ghosh also served as president of the Peptide Therapeutics Foundation.
FinSMEs
22/11/2024